RESUMEN
The incidence of invasive aspergillosis is markedly increasing, and mortality remains dismal. Previously there were only 2 antifungals with activity against Aspergillus, but over the last few years there has been an explosion of newer agents and reformulations of older antifungals. Exploration has also begun with immunotherapy, with use of cytokines and granulocyte transfusions alone or in combination with antifungal therapy. This review will detail the available in vitro, in vivo, and clinical experience with the newer antifungal and immunomodulatory therapies in development for treatment of invasive aspergillosis.
Asunto(s)
Aminoglicósidos , Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Antibacterianos/uso terapéutico , Antifúngicos/clasificación , Aspergilosis/terapia , Azoles/clasificación , Azoles/uso terapéutico , Química Farmacéutica , Citocinas/uso terapéutico , Farmacorresistencia Microbiana , Quimioterapia Combinada , Granulocitos/inmunología , Humanos , Inmunoterapia , Pruebas de Sensibilidad Microbiana , Polienos/clasificación , Polienos/uso terapéuticoRESUMEN
Prompted by the worldwide surge in fungal infections, the past decade has witnessed a considerable expansion in antifungal drug research. New compounds have entered the clinical arena, and major progress has been made in defining paradigms of antifungal therapies. This article provides an up-to-date review on the clinical pharmacology, indications, and dosage recommendations of approved and currently investigational therapeutics for treatment of invasive fungal infections in adult and pediatric patients.